Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 06 04:00PM ET
1.50
Dollar change
0.00
Percentage change
0.00
%
Index- P/E- EPS (ttm)-0.91 Insider Own21.04% Shs Outstand75.00M Perf Week-1.32%
Market Cap112.50M Forward P/E- EPS next Y-0.33 Insider Trans0.00% Shs Float59.22M Perf Month-32.43%
Income-30.15M PEG- EPS next Q-0.06 Inst Own55.92% Short Float1.49% Perf Quarter-29.91%
Sales0.00M P/S- EPS this Y64.83% Inst Trans0.04% Short Ratio3.08 Perf Half Y-12.28%
Book/sh1.12 P/B1.34 EPS next Y37.44% ROA-55.16% Short Interest0.88M Perf Year69.49%
Cash/sh1.13 P/C1.33 EPS next 5Y- ROE-58.98% 52W Range0.79 - 2.75 Perf YTD32.74%
Dividend Est.- P/FCF- EPS past 5Y-26.70% ROI-35.90% 52W High-45.45% Beta2.00
Dividend TTM- Quick Ratio36.91 Sales past 5Y0.00% Gross Margin- 52W Low89.87% ATR (14)0.14
Dividend Ex-Date- Current Ratio36.91 EPS Y/Y TTM29.85% Oper. Margin- RSI (14)33.44 Volatility6.69% 8.85%
Employees5 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price7.12
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q41.06% Payout- Rel Volume0.66 Prev Close1.50
Sales Surprise- EPS Surprise-144.44% Sales Q/Q- EarningsNov 06 AMC Avg Volume285.41K Price1.50
SMA20-9.45% SMA50-20.83% SMA200-19.07% Trades Volume188,295 Change0.00%
Date Action Analyst Rating Change Price Target Change
Nov-25-24Initiated D. Boral Capital Buy $9
May-16-24Initiated Piper Sandler Overweight $4.50
Nov-06-24 04:06PM
Oct-23-24 07:30AM
Oct-16-24 07:30AM
Sep-23-24 07:30AM
Sep-12-24 09:40AM
07:30AM Loading…
Sep-04-24 07:30AM
Aug-27-24 09:40AM
Aug-07-24 04:17PM
Aug-01-24 07:30AM
Jul-10-24 07:30AM
May-30-24 06:11AM
May-22-24 08:50PM
May-20-24 12:00PM
May-14-24 12:00PM
May-08-24 11:56PM
04:06PM Loading…
04:06PM
May-02-24 07:31AM
07:30AM
Apr-01-24 07:30AM
Mar-21-24 01:53PM
07:43AM
Nov-09-23 04:15PM
Oct-31-23 09:00AM
Oct-24-23 12:30PM
Sep-27-23 09:00AM
Aug-10-23 02:19PM
Aug-09-23 04:10PM
Aug-01-23 07:30AM
Jun-13-23 01:34PM
Jun-03-23 08:27AM
04:39PM Loading…
May-10-23 04:39PM
Apr-24-23 12:01PM
Apr-18-23 10:15AM
Apr-04-23 12:00PM
Apr-03-23 07:30AM
Mar-22-23 05:08PM
Mar-15-23 07:30AM
Feb-13-23 08:52AM
Feb-10-23 01:36PM
Feb-07-23 12:21PM
Feb-06-23 07:30AM
Jan-31-23 07:30AM
Jan-09-23 07:30AM
Jan-04-23 07:30AM
Dec-08-22 07:30AM
Nov-29-22 07:30AM
Nov-27-22 07:36AM
Nov-21-22 09:11AM
Nov-09-22 04:14PM
Oct-20-22 07:30AM
Sep-27-22 11:41AM
07:30AM
Sep-06-22 12:50PM
07:30AM
Aug-11-22 04:01PM
Aug-02-22 10:49AM
Jul-05-22 09:22PM
May-15-22 10:12AM
May-11-22 04:01PM
May-05-22 07:30AM
Apr-11-22 07:30AM
Apr-06-22 07:30AM
Mar-30-22 04:33PM
Mar-23-22 04:01PM
Mar-08-22 06:12PM
Feb-22-22 07:30AM
Jan-05-22 04:01PM
Jan-04-22 07:30AM
Dec-10-21 11:11AM
10:11AM
09:54AM
06:45AM
Dec-09-21 06:00PM
Dec-06-21 04:45PM
Dec-02-21 04:01PM
Dec-01-21 06:30PM
Nov-19-21 09:00AM
Nov-01-21 04:02PM
Oct-27-21 07:30AM
Oct-22-21 04:05PM
Oct-20-21 04:57PM
Oct-19-21 07:14PM
Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The firm's robust clinical program for candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. Its ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women?s cancers. The company was founded by Martin Lehr and Felix Kim in April 2015 and is headquartered in Philadelphia, PA.